Ilevro®
Nepafenac 0.3% · ophthalmic suspension
NSAID
Approved uses
Pain and inflammation associated with cataract surgery
One drop QD to the affected eye from 1 day before surgery through the first 2 weeks postoperatively, with an additional drop 30 to 120 minutes preoperatively.
Once-daily dosing is noninferior to TID nepafenac 0.1%, with 91% pain free at day 14.
OFF-LABELNot in the FDA label for this product
Prevention of macular edema after cataract surgery in diabetic retinopathy
One drop QD starting the day before surgery and continued for 90 days after surgery, the regimen used in both trials.
2 RCTs · n=1220 · BCVA mixed
Two prospective, randomized, multicenter, double-masked, vehicle-controlled phase 3 studies in patients with diabetes (615 and 605 patients). Macular edema, defined as a 30% or greater rise in central subfield macular thickness from preoperative baseline, occurred within 90 days in 2.3% versus 17.3% (P < 0.001) and 5.9% versus 14.3% (P = 0.001), pooled 4.1% versus 15.9% (P < 0.001); the endpoint of a 15-letter or greater BCVA improvement, gained through day 14 and maintained through day 90, separated from vehicle in study 1 (61.7% versus 43.0%, P < 0.001) but not in study 2 (48.8% versus 50.5%, P = 0.671).
Contraindications
Previously demonstrated hypersensitivity to any of the ingredients in the formula or to other nonsteroidal anti-inflammatory drugs (NSAIDs)
0.3% ophthalmic suspension, 3 mL in a 4 mL bottle
Nonsteroidal anti-inflammatory prodrug: after topical ocular dosing it penetrates the cornea and is converted by ocular tissue hydrolases to amfenac, an NSAID. Parent drug and amfenac are thought to inhibit prostaglandin H synthase (cyclooxygenase), the enzyme required for prostaglandin production.
Warnings & Precautions
- Corneal effects: Topical NSAIDs may cause keratitis, and continued use in some susceptible patients may result in epithelial breakdown, corneal thinning, corneal erosion, corneal ulceration, or corneal perforation. These events may be sight threatening; patients with evidence of corneal epithelial breakdown should immediately discontinue use and be closely monitored for corneal health.
- Increased risk for corneal adverse events: Postmarketing experience with topical NSAIDs suggests that complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface diseases (e.g., dry eye syndrome), rheumatoid arthritis, or repeat ocular surgeries within a short period of time may increase the risk for corneal adverse events, which may become sight threatening; use with caution in these patients.
- Risk and severity of corneal adverse events: Postmarketing experience with topical NSAIDs also suggests that use more than 1 day prior to surgery or use beyond 14 days post-surgery may increase patient risk and severity of corneal adverse events.
- Increased bleeding time: With some NSAIDs, including ILEVRO 0.3%, there exists the potential for increased bleeding time due to interference with thrombocyte aggregation, and there have been reports that ocularly applied NSAIDs may cause increased bleeding of ocular tissues (including hyphema) in conjunction with ocular surgery. Use with caution in patients with known bleeding tendencies or who are receiving other medications which may prolong bleeding time.
- Delayed healing: Topical NSAIDs may slow or delay healing, and concomitant topical corticosteroids, which also delay healing, may increase the potential for healing problems.
- Contact lens wear: Not to be administered while using contact lenses.
Common Side Effects
The most frequently reported ocular adverse reactions after cataract surgery were capsular opacity, decreased visual acuity, foreign body sensation, increased IOP, and sticky sensation, in approximately 5% to 10% of patients. Other ocular adverse reactions, at an incidence of approximately 1% to 5%, included conjunctival edema, corneal edema, dry eye, lid margin crusting, ocular discomfort, ocular hyperemia, ocular pain, ocular pruritus, photophobia, tearing, and vitreous detachment; some may be the consequence of the cataract surgical procedure. Non-ocular adverse reactions reported at an incidence of 1% to 4% included headache, hypertension, nausea/vomiting, and sinusitis.
Pregnancy: Category C; reproduction studies in rabbits and rats at oral doses up to 10 mg/kg/day revealed no evidence of teratogenicity despite maternal toxicity, but in rats maternally toxic doses greater than or equal to 10 mg/kg were associated with dystocia, increased postimplantation loss, reduced fetal weights and growth, and reduced fetal survival, and nepafenac crosses the placental barrier in rats. There are no adequate and well-controlled studies in pregnant women; use only if the potential benefit justifies the potential risk to the fetus, and avoid use during late pregnancy because prostaglandin biosynthesis inhibiting drugs affect the fetal cardiovascular system (closure of the ductus arteriosus).
Lactation: Excreted in the milk of lactating rats; excretion in human milk is not known, so use caution in a nursing woman.
Safety and effectiveness below age 10 not established.